Skip to main content
. 2009 Feb 18;2:171–178. doi: 10.2147/ott.s4503

Table 5.

Phase II combination studies of bortezomib

Patient population Metastatic colorectal cancer Metastatic pancreatic carcinoma Pretreated NSCLC
Number of patients 68 87 155
Schedule Arm 1: 1.5 mg/m2 on days 1, 4, 8, 11 q21 days Arm 2: 1.3 mg/m2 on days 1, 4, 8, 11 + CPT 11 125 mg/m2 on day 1 q21 days Arm 1: 1.5 mg/m2 on days 1, 4, 8, 11 q21 days Arm 2: 1.3 mg/m2 on days 1, 4, 8, 11 + gemcitabine 1000 mg/m2 on day 1 q21 days Arm 1: 1.5 mg/m2 on days 1, 4, 8, 11 q21 days Arm 2: 1.3 mg/m2 on days 1,4,8,11 + docetaxel 75 mg/m2 on day 1 q21
Response rates % NA 10% RR 42% RR
Toxicity observed Hematologic, neurotoxicity and fatigue Abdominal pain, fatigue and thrombocytopenia Neutropenia, neurotoxicity and fatigue

Abbreviations: RR, response rate; CPT, irinotecan.